

Quercetin reverses 5-fluorouracil resistance in colon cancer cells by modulating the NRF2/HO-1 pathway

Zhongzhu Tang, Lei Wang, Yunwang Chen, Xiaomin Zheng, Runyu Wang, Bingxue Liu, Shiqi Zhang, Huimin Wang Department of Radiotherapy, Tongde Hospital Zhejiang Provincial, Hangzhou, Zhejiang, China

Quercetin (Que) has been proven to enhance the chemosensitivity of multiple cancers, including colon cancer (CC). However, whether the combination of Que and 5-fluorouracil (5-FU) has a synergistic effect on drugresistant CC cells has not previously been reported. The effect of Que (5 and 10 µg/mL) on cell vitality and apoptosis of CC and 5-FU-resistant CC cells was examined using a cell counting kit-8 (CCK-8) and flow cytometry. After cells were treated with 5-FU (10, 40 µg/mL), Que (10 µM, 40 µM), or 5-FU in combination with Que, cell proliferation, apoptosis, oxidative stress-related factors, reactive oxygen species (ROS), and nuclear factor erythroid 2-related factor (Nrf2)/heme oxygenase-1 (HO-1) pathway-related factors were examined by colony formation assay, flow cytometry, ELISA, ROS kit, immunofluorescence assay, and Western blot. The results showed that 5-FU reduced cell viability and induced apoptosis of CC as well as 5-FU-resistant CC cells. Que further restrained the proliferation, oxidative stress-related factors (SOD, CAT, GPx, and GR), ROS production, and induced apoptosis in CC cells and 5-FU-resistant CC cells induced by 5-FU. Moreover, the combination of Que and 5-FU attenuated the Nrf2/HO-1 pathway-related marker levels in CC cells and 5-FU-resistant CC cells. Therefore, our results suggest that Que reverses 5-FU resistance in CC cells *via* modulating the Nrf2/HO-1 pathway.

Key words: colon cancer; quercetin; 5-fluorouracil; chemosensitivity; nuclear factor erythroid 2-related factor/heme oxygenase-1 pathway.

Correspondence: Huimin Wang, Department of Radiotherapy, Tongde Hospital Zhejiang Provincial, No.234, Gucui Road, Xihu District, 310014 Hangzhou, Zhejiang, China. Email: wanghuimin927@sina.com

Contributions: ZT, HW, conception and design of the research, manuscript drafting and revision for important intellectual content; LW, YC, XZ, RW, BL, SZ,data acquisition, analysis and interpretation, statistical analysis All the authors read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work.

Conflict of interest: the authors declare no conflict of interest.

Availability of data and material: the analyzed data sets generated during the present study are available from the corresponding author upon reasonable request.



Introduction

Colon cancer (CC) is the third most common malignancy in men and the second most common cancer in the world.¹ At present, the pathogenic factors of CC include a high-fat diet, insufficient fiber intake, unhealthy lifestyle, and the interaction between genetic and environmental factors.² The early symptoms of CC patients are not obvious; approximately 40% of patients can be diagnosed and treated at the early stage of the disease, and the survival rate of advanced patients is as low as 12.5%.^{3,4} According to the Guidelines for the Diagnosis and Treatment of Colorectal Cancer by the Chinese Society of Clinical Oncology and Clinical Practice Guidelines of American Society of Cataract and Refractive Surgery, for adjuvant therapy, 5-fluorouracil (5-FU) is the major chemotherapeutic drug recommended for use. 5-FU can block the DNA synthesis and proliferation of cancer cells by interfering with their nucleic acid metabolism.5 However, chemotherapeutic drugs are considered a "double-edged sword". Adverse reactions also occur when cancer cells are inhibited. The insensitivity of CC cells to 5-FU is the main reason for the decreased survival rate in CC patients.⁶ Thus, searching for effective anticancer drugs from natural plants is a research hotspot for clinical and scientific researchers worldwide. Owing to advantages such as multi-targeting and few adverse reactions, the reversal effect of natural drug ingredients on tumor resistance has also attracted extensive attention.

Quercetin (Que) is a plant-derived flavonoid that widely exists in fruits, vegetables, grains, and other plants.⁷ It has been reported to have various pharmacologic effects, such as free radical scavenging, anti-hypertensive, blood lipid reducing, antiinflammatory, anti-allergic, anti-viral, and anti-platelet aggregation activities, which are of great importance in the treatment and prevention of human diseases, including cancers.^{8,9} Researchers have summarized that Que exerts anti-tumor effects by altering cell cycle progression, inhibiting cell proliferation, promoting apoptosis, inhibiting angiogenesis and metastasis progression, and affecting autophagy.¹⁰ As early as 1994, several scholars preliminarily studied the inhibitory effects of Que and 5-FU on CC cells, and recent research has more clearly identified the anti-CC effects of Que.¹¹ Que evidently has an inhibitory function on the proliferation and induction of apoptosis in various CC cell lines, such as SW480, HCT-116, Caco-2, LOVO, and HT-29.12-15 More importantly, researchers revealed that Que is an effective reversal agent for multidrug resistance (MDR), which enhances the sensitivity to chemotherapy drugs in breast cancer, CC, and nasopharyngeal cancer, among other cancers.¹⁶⁻¹⁸ Regulation of MDR-related transporter expressions, such as that of P-gp, MRP1 and BCRP, is considered as the underlying mechanism for reversing MDR.19 However, it has not yet been reported whether the combination of Que and 5-FU has a synergistic effect on HCT-116 drug-resistant cells. Therefore, in this study, we induced a 5-FU-resistant human CC cell model, observed the reversal effect of Que on 5-FU induced resistance on CC cells, and explored the possible mechanism.

Materials and Methods

Cell culture and reagents

HCT-116 cells were provided by the iCell Bioscience, Inc. (Shanghai, China) and cultured in DMEM medium (SH30243.01, Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS, 11011-8615, Tianhang, China), and a trypsin solution

(0.25%, SH30042.01, Hyclone, USA) was used to detach the cells. The HCT-116 cells were then placed in a cell incubator (BB150, Thermo Fisher Scientific, Waltham, MA, USA).

5-FU (F100149, Aladdin, Shanghai, China, CAS ID 51-21-8) and Que (Q111274, Aladdin, China, CAS ID 117-39-5) were prepared as stock solutions in DMSO (D8371, Solarbio, Beijing, China). For each experiment, a medium was used to dilute the stock solutions to a final DMSO concentration of 0.5% (v/v).

Construction of HCT116 drug-resistant cell line

To construct a 5-FU-resistant HCT116 cell (HCT116-R), HCT116 cells from the same batch were first stimulated with 10 μ M 5-FU and then reacted with gradually increasing concentrations of 5-FU (20, 40, 60, 80, and 100 μ M) over a period of 8 months. Thereafter, the surviving 5-FU-resistant HCT116 cells were maintained at a concentration of 60 μ M 5-FU and then used for subsequent experiments.²⁰

Experimental design

First, HCT116 and HCT116-R cells were subjected to 0, 5, and 10 μ M 5-FU for 72 h to choose 10 μ M as a suitable concentration for 5-FU. After that, HCT116 and HCT116-R cells were each exposed to 10 μ M 5-FU (5-FU group), 10 μ M Que (Que 10 group), 40 μ M Que (Que 40 group), 10 μ M Que + 10 μ M 5-FU (Que 10 + 5-FU group), or 40 μ M Que + 10 μ M 5-FU (Que 40 + 5-FU group) for 72 h. Each experiment was repeated three times, except for the cell viability assay that was repeated six times.

Cell viability assay

Chemosensitivity was assessed using a cell counting kit-8 (CCK-8) (HY-K0301, MedChemExpress, Monmouth Junction, NJ, USA). The cells were seeded in 96-well plates $(1 \times 10^4 \text{ cells/mL})$ and processed according to the experimental design described above. Afterwards, treated cells were exposed to 10 μ L CCK-8 solution and stored in the cell incubator for 3 h. Lastly, the absorbance (450 nm) was estimated using a microplate reader (CMaxPlus, Molecular Devices, San Jose, CA, USA).

Apoptosis assay

An apoptosis kit (556547, BD Biosciences, San Jose, CA, USA) was used to evaluate apoptosis. Cells cultured in 96-well plates (1.5×10^6 cells/mL) were treated according to the experimental design described above. After the cells were harvested, washed, and centrifuged, their concentration was adjusted to 1×10^6 cells/mL. After centrifugation, the precipitated cells of each hole were added to 100 µL of binding buffer. Thereafter, each sample tube was subjected to 5 µL Annexin V-FITC and 10 µL propidium iodide and then placed away from light for 15 min at 37°C. After adding 1× binding buffer, flow cytometry (C6, BD Biosciences, Franklin Lakes, NJ, USA) was used to analyze apoptosis.

The colony formation assay

Cells seeded into 12-well plates (8 ×10² cells/well) were treated based on the experimental design as described above. After 14 days of culture, the cells in each well were fixed with 75% alcohol (A171299, Aladdin, China) for 1 h and then stained with 0.25% crystal violet (C8470, Solarbio, China) for 2 min. Finally, images were captured and observed using an optical microscope (AE2000, Motic, Wetzlar, Germany).

ELISA

Superoxide dismutase (SOD) kit (A001-3), catalase (CAT) kit (A007-1-1), glutathione peroxidase (GPx) kit (A005-1), and glutathione reductase (GR) kits (A062-1-1) were obtained from



Jiancheng (Nanjing, China). Cells were seeded in 12-well plates $(1 \times 10^4 \text{ cells/mL})$ and treated as described above, thereafter the cells in each well were harvested, washed, and centrifuged, and supernatants were collected. Then, the levels of SOD, CAT, GPx, and GR were then measured using the related kits.

Detection of reactive oxygen species (ROS)

A ROS kit (S0033M, Beyotime, Shanghai, China) was used to examine the ROS production in each group of cells. After the cells in each group (1×10^4) were administered, the medium was removed and 1 mL of the prepared DCFH-DA diluent was added.

Then, they were displayed in the cell incubator for 20 min. Cells were washed three times with serum-free cell culture medium to adequately remove DCFH-DA that had not entered the cells. Then, the cells were detached by 0.25% trypsin, and the cell suspension was subsequently transferred to a 5 mL flow tube and assayed on a flow cytometer.

Immunofluorescence assay

After treatment, the culture medium was discarded and 1-2 mL of pre-chilled 4% paraformaldehyde was added to each well; fixation lasted 10 min at room temperature, then PBS was used for



Figure 1. 5-FU blunted the cell vitality of CC cells HCT116 and 5-FU-resistant CC cells HCT116-R. The CCK-8 assay was used to examine the cell viability of CC cells (A) and 5-FU-resistant CC cells (B) after 5-FU (0, 5, and 10 μ g/mL) treatment; n=6. 5-FU, 5-fluorouracil; CC, colon cancer; CCK-8, cell counting kit-8; Δp <0.05, $\Delta \Delta p$ <0.01 *vs* 0 μ M.



Figure 2. 5-FU induced apoptosis of CC cells and 5-FU-resistant CC cells. The flow cytometer method was used to examine apoptosis of CC cells (A) and 5-FU-resistant CC cells (B) after 5-FU (0, 5, and 10 μ M) treatment; n=3. 5-FU, 5-fluorouracil; CC, colon cancer; \blacktriangle p<0.05, \bigstar p<0.01 vs 0 μ M.





rinsing three times for 5 min each. Then 1-2 mL of 0.5% Triton X-100 was added to each well for 2 min at room temperature for permeabilization, and the cells were rinsed with PBS three times for 5 min each. Afterward, the primary antibody against nuclear factor erythroid 2-related factor 2 (Nrf2, 1:500, ab62352, Abcam, Cambridge, UK) and heme oxygenase 1 (HO-1, 1:200, ab68477, Abcam) was added overnight at 4°C, followed by incubation with a secondary antibody Goat Anti-Rabbit IgG H&L (Alexa Fluor[®] 488) (1:500, ab150077, Abcam) for 1 h at 37°C. Nuclei were stained with DAPI solution (5 µg/mL) for 5 min in the dark, at room temperature. Omitting the primary antibody was used as the negative control. Cells were observed under a microscope, and the immunofluorescence intensity was assessed by Image J software.

Western blot

After treatment, the cells were harvested and lysed using a cell buffer (WB038, GEFAN, Nanjing, China), and their concentrations were estimated by a BCA kit (GM03, GEFAN). After denaturation, cells were subjected to protein electrophoresis. After transferring to a PVDF membrane (WB041, GEFAN), the membrane was sealed with 5% skim milk. After 2 h, cells were reacted with primary antibodies overnight at 4°C followed by incubation with a goat anti-rabbit secondary antibody IgG H&L (1:3000, S0001, Affinity Biosciences, Cincinnati, OH, USA) for 1 h at 37°C. Finally, a color reagent (E266188, Aladdin, Shanghai, China) was used to visualize the bound antibodies, which were then placed in a chemiluminescent instrument (610020-9Q, Clinx, Shanghai, China). The primary antibodies of the rabbit anti-human Nrf2 (1:2000, AF0639), SOD-1 (1:1500, AF5198), CAT (1:2000, AF7746), HO-1 (1:1500, AF5393), nuclear factor kappa B (NF- κ B, 1:1500, AF5006), phospho-IkappaB-alpha (p-IKB α , 1:2000, AF2002), and GAPDH (1:20000, AF7021) were obtained from Affinity Biosciences .

Statistical analysis

Statistical analysis was performed using SPSS software (version 16.0, IBM, Armonk, NY, USA). Comparisons between more than two groups were performed using one-way ANOVA. Comparisons between the groups were analyzed using Tukey's test. Data are expressed as mean \pm standard deviation. A p<0.05 was designated as statistically significant.

Results

5-FU blunted the cell vitality and induced apoptosis of CC cells and 5-FU-resistant CC cells

First, we estimated the role of 5-FU (5 and 10 μ M) on the cell vitality and demonstrated that 5-FU obviously alleviated the vitality of CC cells and 5-FU-resistant CC cells (Figure 1 A,B, p<0.05). The inhibitory effect of 5-FU on CC cell viability was stronger than that on 5-FU-resistant CC cells (Figure 1 A,B, p<0.05). Second, we examined apoptosis and confirmed that 5-FU (5 and 10 μ M) induced apoptosis of CC cells, and 10 μ M 5-FU also notably facilitated apoptosis of 5-FU-resistant CC cells (Figure 2 A,B, p<0.05).



Figure 3. Que further restrained the proliferation of CC cells and 5-FU-resistant CC cells induced by 5-FU. After the cells were treated with 5-FU, Que, or Que plus 5-FU, a colony formation assay was performed to examine the proliferation of CC cells (**A**,**C**) and 5-FU-resistant CC cells (**B**, **D**); n=3. Que, quercetin; 5-FU, 5-fluorouracil; CC, colon cancer. $\Delta p < 0.05$, $\Delta \Delta p < 0.01$ *vs* control; #p < 0.05, ##p < 0.01 *vs* 5-FU.



Que restrained the proliferation and induced apoptosis of CC and 5-FU-resistant CC cells

CC cells and 5-FU-resistant CC cells further were exposed to 10 μ M 5-FU, 10 μ M Que, 40 μ M Que, 10 μ M Que +10 μ M 5-FU, or 40 μ M Que + 10 μ M 5-FU for 72 h, respectively. As shown in Figure 3 A-D, it was manifested in the colony formation assay that 5-FU greatly blunted the proliferation of CC cells but did not obviously affect the proliferation of 5-FU-resistant CC cells. And 10 μ M Que and 40 μ M Que both evidently weakened the proliferation

of CC cells and 5-FU-resistant CC cells (p<0.05). More importantly, the combined application of Que and 5-FU inhibited the colony number to a greater extent than treatment with 5-FU alone, particularly in the 5-FU + 40 μ M Que group (Figure 3, p<0.05). The flow cytometer assay revealed that 5-FU treatment induced apoptosis in HCT116 cells, but not in HCT116-R cells, and the apoptotic rate of HCT116 and HCT116-R cells in the Que 40 + 5-FU combination group was higher than that in the 5-FU group (Figure 4 A,B, p<0.05).



Figure 4. Que further induced apoptosis of CC cells and 5-FU-resistant CC cells induced by 5-FU. After the cells were treated with 5-FU, Que, or Que plus 5-FU, the flow cytometry method was used to examine the apoptosis of CC cells (**A**) and 5-FU-resistant CC cells (**B**); n=3. Que, quercetin; 5-FU, 5-fluorouracil; CC, colon cancer. $\blacktriangle \Rightarrow p < 0.01$ vs control; #p < 0.05, ##p < 0.01 vs 5-FU.



Figure 5. Que further weakened the contents of oxidative stress-related factor of CC cells and 5-FU-resistant CC cells induced by 5-FU. After the cells were treated with 5-FU, Que, or Que plus 5-FU, ELISA kit was used to examine the levels of oxidative stress-related factor of CC cells (A) and 5-FU-resistant CC cells (B); n=6. Que, quercetin; 5-FU, 5-fluorouracil; CC, colon cancer. $\Delta p < 0.05$, $\Delta \Delta p < 0.01 vs$ control; #p < 0.05, #p < 0.01 vs 5-FU.





Que alleviated oxidative stress and ROS production of CC cells and 5-FU-resistant CC cells

As displayed in Figure 5 A,B, the ELISA assay demonstrated that 5-FU, Que and Que + 5-FU treatment inhibited the activity and contents of SOD, CAT, GPx, and GR contents in CC and 5-FU-resistant CC cells (p<0.05). What's more, the inhibitory effects of the combination group (40 μ M Que + 10 μ M 5-FU) on the SOD, CAT, GPx, and GR contents in CC cells and 5-FU-resistant CC cells were stronger than 5-FU alone (p<0.05). Next, we assessed the ROS production and found that the fluorescence intensity of CC cells and 5-FU-resistant CC cells in the 5-FU group and Que 40 group was lower than that in the control group (Figure 6 A,B, p<0.05). Meanwhile, the fluorescence intensity of 5-FU-resistant CC cells in the Que 40 + 5-FU group was lower than that in the 5-FU group (Figure 6 A,B, p<0.05).

Que suppressed the Nrf2/HO-1 pathway-related marker levels of CC cells and 5-FU-resistant CC cells

We further detected the expression of oxidative stress-related Nrf2/HO-1 signaling in CC cells and 5-FU-resistant CC cells. The results in Figure 7 A-D showed that the relevant fluorescence intensities of Nrf2 and HO-1 were both decreased after Que treatment in CC and 5-FU-resistant CC cells (p<0.01), but 5-FU inhibited the Nrf2 and HO-1 expression only in CC cells. However, the addition of Que to 5-FU significantly suppressed the fluorescence intensity of Nrf2 and HO-1 in both CC cells and 5-FU-resistant CC cells compared to the 5-FU group (p<0.01). We also tested the Nrf2/HO-1 pathway-related protein expression and confirmed that the expression of Nrf2, SOD-1, CAT, HO-1, NF-κB, and p-IKBα in CC cells of the 5-FU group and Que 40 group were lower than the control group (Figure 8A, p<0.05). Compared with the 5-FU group, the Nrf2, SOD-1, CAT, HO-1, and NF-KB levels of CC cells were further decreased but the p-IKBa level of CC cells was enhanced in the Que 40 + 5-FU group (Figure 8A, p<0.05). For the 5-FU-resistant CC cells, 5-FU obviously blunted the NF-kB and pIKB α levels (Figure 8B, p<0.05), but did not affect the Nrf2, SOD-1, CAT, and HO-1 levels. The combination of Que and 5-FU further reduced the Nrf2, SOD-1, CAT, HO-1, and p-IKB α levels compared to the 5-FU group (Figure 8B, p<0.05).

Discussion

At present, the treatment options for CC remain limited, and the first choice is mainly surgical resection, as well as adjuvant therapy including 5-FU, mitomycin, Me-CCNu, and antigen-specific immunotherapy.²¹ Although these treatment methods have achieved certain therapeutic effects, there are still limitations. When killing cancer cells, the long-term use of chemotherapeutic drugs leads to the development of MDR in cancer cells and reduces their sensitivity. Therefore, it is of profound theoretical and practical significance to identify for natural and effective botanical compounds that can reverse MDR in CC. In this study, we investigated Que as a 5-FU sensitizer for CC cell treatment.

Que has been corroborated with the potential to reverse the MDR. Lan et al. manifested that in pancreatic cancer cells and gemcitabine-resistant pancreatic cancer cells, Que facilitated cell cycle arrest, autophagy, apoptosis, and enhanced gemcitabine chemosensitivity.22 For tamoxifen-resistant breast cancer cells, Que notably lessened the proliferation and enhanced apoptosis of cells, illustrating that Que intensified the chemosensitivity of breast cancer cells.23 Shu et al. clarified that co-treatment of doxorubicin and Que induces apoptosis of doxorubicin-resistant prostate cancer cells via repressing c-met expression and PI3K/AKT pathway, illustrating that Que could reverse the drugresistance of prostate cancer cells.²⁴ Our study complemented the deficiency of Que and 5-FU combination therapy in 5-FU-resistant HCT-116 cells. We demonstrated that 5-FU blunted the cell proliferation and induced apoptosis in CC cells and 5-FU-resistant CC cells, while its anti-cancer effect on 5-FU-resistant CC cells was weaker than that on normal CC cells. More importantly, co-treat-



Figure 6. Que further weakened the ROS production of CC cells and 5-FU-resistant CC cells induced by 5-FU After the cells were treated with 5-FU, Que, or Que plus 5-FU, reactive oxygen species (ROS) assay was used to examine the ROS production in CC cells (A) and 5-FU-resistant CC cells (B). n=3. Que: quercetin; 5-FU: 5-fluorouracil, CC: colon cancer. $\triangle P < 0.05$, $\triangle \triangle P < 0.01$ *vs* control; #P < 0.05 *vs* 5-FU.



ment with Que and 5-FU notably restrained the proliferation and induced apoptosis of 5-FU-resistant CC cells, indicating that Que could reverse the 5-FU-resistance in CC cells. For MDR in CC cells, Zhou *et al.* also demonstrated that the combination of Que and doxorubicin enhanced the chemosensitivity of CC cells, regulation of P-glycoprotein and SLC1A5 expression was considered as the underlying mechanism.¹⁶ Another study also demonstrated that Que potentiates 5-FU effects in human CC cells, which would be associated with the miR-27a/ Wnt/ β -catenin signaling pathway.²⁵ In our study, we speculate that oxidative stress regulation is the major mechanism for reverse 5-FU resistant in HCT 116 cells.

In recent years, researchers have gradually realized the role of oxidative stress in tumorigenesis, and genes related to oxidative stress pathways are expected to become new targets for tumor drug chemotherapy. Oxidative stress refers to the excessive production of ROS in the body when the body is subjected to various harmful stimuli, and the degree of oxidation exceeds the ability to remove oxides, thus leading to tissue damage.²⁶ ROS can be produced by cancer cells by the increased mitochondrial activity and accelerated metabolism required for tumor growth and cell proliferation, which facilitates the initiation and development of cancer.²⁷ GPx is a clear ROS scavenger that can mediate the development of cisplatin resistance.^{28,29} It has previously been confirmed that Nrf2 is involved in the regulation of GPx level, and the activation of Nrf2 can lead to a high dependence on GPx in cells.³⁰ NRF2 is a transcription factor containing a basic leucine zipper structure, which is a key protein for the basic expression of oxidative stress.³¹ Research on Nrf2 in tumors has illustrated that abnormal expres-



Figure 7. The combination of Que and 5-FU attenuated the Nrf2 and HO-1 expression in CC cells and 5-FU-resistant CC cells. After the cells were treated with 5-FU, Que, or Que plus 5-FU, immunofluorescence assay was used to examine the expression of nuclear factor erythroid 2-related factor (Nrf2) and heme oxygenase-1 (HO-1) in CC cells (**A**) and 5-FU-resistant CC cells (**B**). n=3. Que: quercetin; 5-FU: 5-fluorouracil, CC: colon cancer. $\blacktriangle \bowtie P < 0.01$ *vs* control; ##P<0.01 *vs* 5-FU.



sion of Nrf2 can promote tumor proliferation and metastasis, and it is associated with chemotherapy resistance and poor prognosis.³²⁻³⁴ Many antioxidant proteins encoded by Nrf2-dependent genes, such as HO-1 and SOD, can make cells resist oxidative stress and assist the body to maintain oxidation-reduction homeostasis.^{35, 36} Abbasi *et al.* proposed that co-treatment of vitamin C and Que attenuated the activities of GPX and GR and the expression of Nrf2 mRNA and protein in prostate cancer cells.³⁷ It was illustrated in another study that Que mitigated the oxidative stress and DNA damage in CC rats triggered by 1,2-dimethylhydrazine by modulating the Nrf2 pathway.³⁸ In our study, we discovered for the first time that co-treatment of Que and 5-FU weakened the contents of oxidative stress-related factors (SOD, CAT, GPx, and GR) and ROS production of CC cells and 5-FU-resistant CC cells. We further demonstrated that the combination of Que and 5-FU attenuated the Nrf2, SOD-1, CAT, HO-1, NF- κ B, and p-IKB α expressions of 5-FU-resistant CC cells.

In summary, our research observed that *in vitro* experiments using Que combined with 5-FU on 5-FU-resistant HCT-116 cells showed a good synergistic effect. The application of natural compounds in chemotherapy has good clinical application prospects for reducing toxicity and adverse reactions, as well as enhancing curative sensitivity. However, the interaction between Que and 5-FU at different concentrations requires further investigation.



Figure 8. The combination of Que and 5-FU attenuated the Nrf2/HO-1 pathway-related marker levels of CC cells and 5-FU-resistant CC cells. After cells were treated with 10 µg/mL 5-FU, 40 µM Que, or 40 µM Que plus 10 µg/mL 5-FU, Western blotting was used to examine the Nrf2/HO-1 pathway-related factors level in CC cells (**A**) and 5-FU-resistant CC cells (**B**); n=3. Que, quercetin; 5-FU, 5-fluorouracil; CC, colon cancer. $\blacktriangle p < 0.05$, $\bigstar \blacklozenge p < 0.01$ vs control; #p < 0.05, ##p < 0.01 vs 5-FU.



References

- Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017;66:683-91.
- Endo H, Hosono K, Fujisawa T, Takahashi H, Sugiyama M, Yoneda K, et al. Involvement of JNK pathway in the promotion of the early stage of colorectal carcinogenesis under high-fat dietary conditions. Gut 2009;58:1637-43.
- Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014;64:104-17.
- Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403.
- Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996-2004.
- Manoochehri M, Karbasi A, Bandehpour M, Kazemi B. Downregulation of BAX gene during carcinogenesis and acquisition of resistance to 5-FU in colorectal cancer. Pathol Oncol Res 2014;20:301-7.
- Sultana B, Anwar F. Flavonols (kaempeferol, quercetin, myricetin) contents of selected fruits, vegetables and medicinal plants. Food Chem 2008;108:879-84.
- Baran I, Ganea C, Scordino A, Musumeci F, Barresi V, Tudisco S, et al. Effects of menadione, hydrogen peroxide, and quercetin on apoptosis and delayed luminescence of human leukemia Jurkat T-cells. Cell Biochem Biophys 2010;58:169-79.
- 9. Russo M, Spagnuolo C, Tedesco I, Bilotto S, Russo GL. The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem Pharmacol 2012;83:6-15.
- Tang SM, Deng XT, Zhou J, Li QP, Ge XX, Miao L. Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects. Biomed Pharmacother 2020;121:109604.
- Boersma HH, Woerdenbag HJ, Bauer J, Scheithauer W, Kampinga HH, Konings AW. Interaction between the cytostatic effects of quercetin and 5-fluorouracil in two human colorectal cancer cell lines. Phytomedicine 1994;1(3):239-44.
- Kim HS, Wannatung T, Lee S, Yang WK, Chung SH, Lim JS, et al. Quercetin enhances hypoxia-mediated apoptosis via direct inhibition of AMPK activity in HCT116 colon cancer. Apoptosis 2012;17:938-49.
- Dihal AA, Woutersen RA, van Ommen B, Rietjens IM, Stierum RH. Modulatory effects of quercetin on proliferation and differentiation of the human colorectal cell line Caco-2. Cancer Lett 2006;238:248-59.
- Zhang H, Zhang M, Yu L, Zhao Y, He N, Yang X. Antitumor activities of quercetin and quercetin-5',8-disulfonate in human colon and breast cancer cell lines. Food Chem Toxicol 2012;50:1589-99.
- 15. Shan BE, Wang MX, Li RQ. Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest 2009;27:604-12.
- 16. Zhou Y, Zhang J, Wang K, Han W, Wang X, Gao M, et al. Quercetin overcomes colon cancer cells resistance to chemotherapy by inhibiting solute carrier family 1, member 5 transporter. Eur J Pharmacol 2020;881:173185.
- 17. Rani Inala MS, Pamidimukkala K. Amalgamation of quercetin with anastrozole and capecitabine: A novel combination to treat

breast and colon cancers - an in vitro study. J Cancer Res Ther 2023;19:S93-S105.

- Li T, Li Y. Quercetin acts as a novel anti-cancer drug to suppress cancer aggressiveness and cisplatin-resistance in nasopharyngeal carcinoma (NPC) through regulating the yesassociated protein/Hippo signaling pathway. Immunobiology 2023;228:152324.
- 19. Chen C, Zhou J, Ji C. Quercetin: a potential drug to reverse multidrug resistance. Life Sci 2010;87:333-8.
- Riahi-Chebbi I, Souid S, Othman H, Haoues M, Karoui H, Morel A, et al. The phenolic compound Kaempferol overcomes 5-fluorouracil resistance in human resistant LS174 colon cancer cells. Sci Rep 2019;9:195.
- 21. Saini A, Norman AR, Cunningham D, Chau I, Hill M, Tait D, et al. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 2003;88:1859-65.
- 22. Lan CY, Chen SY, Kuo CW, Lu CC, Yen GC. Quercetin facilitates cell death and chemosensitivity through RAGE/PI3K/AKT/mTOR axis in human pancreatic cancer cells. J Food Drug Anal 2019;27:887-96.
- Wang H, Tao L, Qi K, Zhang H, Feng D, Wei W, et al. Quercetin reverses tamoxifen resistance in breast cancer cells. J BUON 2015;20:707-13.
- 24. Shu Y, Xie B, Liang Z, Chen J. Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c-met. Oncol Lett 2018;15:2252-8.
- 25. Terana GT, Abd-Alhaseeb MM, Omran GA, Okda TM. Quercetin potentiates 5-fluorouracil effects in human colon cancer cells through targeting the Wnt/β-catenin signalling pathway: the role of miR-27a. Contemp Oncol (Pozn) 2022;26:229-38.
- 26. Cai L, Kang YJ. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol 2001;1:181-93.
- 27. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991;51:794-8.
- 28. Pan H, Kim E, Rankin GO, Rojanasakul Y, Tu Y, Chen YC. Theaflavin-3,3'-digallate enhances the inhibitory effect of cisplatin by regulating the copper transporter 1 and glutathione in human ovarian cancer cells. Int J Mol Sci 2018;19:1-12.
- 29. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992;89:3070-4.
- Bansal A, Simon MC. Glutathione metabolism in cancer progression and treatment resistance. J Cell Biol 2018;217:2291-8.
- 31. Cho HY, Reddy SP, Kleeberger SR. Nrf2 defends the lung from oxidative stress. Antioxid Redox Signal 2006;8:76-87.
- 32. Syu JP, Chi JT, Kung HN. Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia. Oncotarget 2016;7:14659-72.
- 33. Shibata T, Kokubu A, Saito S, Narisawa-Saito M, Sasaki H, Aoyagi K, et al. NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia 2011;13:864-73.
- 34. Zhang M, Zhang C, Zhang L, Yang Q, Zhou S, Wen Q, et al. Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma. BMC Cancer 2015;15:531.
- 35. Joung EJ, Li MH, Lee HG, Somparn N, Jung YS, Na HK, et al. Capsaicin induces heme oxygenase-1 expression in HepG2 cells via activation of PI3K-Nrf2 signaling: NAD(P)H:quinone oxidoreductase as a potential target. Antioxid Redox Signal



2007;9:2087-98.

- Shen G, Kong AN. Nrf2 plays an important role in coordinated regulation of Phase II drug metabolism enzymes and Phase III drug transporters. Biopharm Drug Dispos 2009;30:345-55.
- 37. Abbasi A, Mostafavi-Pour Z, Amiri A, Keshavarzi F, Nejabat N, Ramezani F, et al. Chemoprevention of prostate cancer cells by vitamin C plus quercetin: role of Nrf2 in inducing oxidative

stress. Nutr Cancer 2021;73:2003-13.

38. Darband SG, Sadighparvar S, Yousefi B, Kaviani M, Ghaderi-Pakdel F, Mihanfar A, et al. Quercetin attenuated oxidative DNA damage through NRF2 signaling pathway in rats with DMH induced colon carcinogenesis. Life Sci 2020; 253:117584.

Received: 21 March 2023. Accepted: 28 June 2023. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). ©Copyright: the Author(s), 2023 Licensee PAGEPress, Italy European Journal of Histochemistry 2023; 67:3719 doi:10.4081/ejh.2023.3719

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

